BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, December 29, 2025
Home » Topics » Financings

Financings
Financings RSS Feed RSS

Hong Kong diagnostic company Prenetics sees stock fall nearly 30% after Nasdaq listing

May 20, 2022
By Tamra Sami
After listing on the Nasdaq market on May 18, Hong Kong-based diagnostics and genetic testing company Prenetics Group Ltd. saw its shares fall nearly 30% in early trading, dropping from $8.40 per share on listing to $5.70 by the end of trading May 19. Trading under the ticker PRE, Prenetics formed a merger with Artisan Acquisition Corp., a special purpose acquisition company, which was founded by entrepreneur Adrian Cheng. The transaction values Prenetics at an enterprise value of $1.25 billion, making the company the first Hong Kong unicorn to list on the Nasdaq.
Read More

Financings for May 20, 2022

May 20, 2022
Med-tech firms raising money in public or private financings, including: Babylon.
Read More

Financings for May 20, 2022

May 20, 2022
Biopharmas raising money in public or private financings, including: Cinclus, Evofem, Hemostemix, Okyo.
Read More

Financings for May 19, 2022

May 19, 2022
Med-tech firms raising money in public or private financings, including: Apiject Systems, Deciphex, Eurobio Scientific, Predictive Oncology.
Read More

Financings for May 19, 2022

May 19, 2022

Biopharmas raising money in public or private financings, including: Biofrontera, Mydecine Innovations, Oviva, Zentalis.


Read More
DNA illustration

Swanbio closes $56M series B round to move AMN gene therapy to the clinic

May 18, 2022
By Cormac Sheridan
Swanbio Therapeutics Inc. closed a $56 million series B round to take its lead gene therapy program, SBT-101, into clinical development later this year. The candidate, comprised of an adeno-associated virus type 9 vector encoding the ABCD1 peroxisomal ATP-binding cassette transporter, is in development for adrenomyeloneuropathy (AMN), an inherited disease that affects the central nervous system.
Read More

Financings for May 18, 2022

May 18, 2022
Biopharmas raising money in public or private financings, including: Appili, Baudax, Celularity, Laekna, Locus, Tenax.
Read More

UK biotech RQ Bio emerges with $157M COVID-19 antibody deal with Astrazeneca

May 17, 2022
By Richard Staines
An unknown U.K. biotech, RQ Biotechnology Ltd., has emerged from stealth mode with a $157 million licensing deal with Astrazeneca plc for its monoclonal antibodies, aimed at protecting vulnerable and immunosuppressed people against SARS-CoV-2.
Read More

Financings for May 17, 2022

May 17, 2022
Med-tech firms raising money in public or private financings, including: Mirvie, Vivasure Medical.
Read More

Financings for May 17, 2022

May 17, 2022

Biopharmas raising money in public or private financings, including: Okyo, Remix, Tetra, Vyriad.


Read More
Previous 1 2 … 345 346 347 348 349 350 351 352 353 … 640 641 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 29, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Businessman, businesswoman handshake

    Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact

    BioWorld
    Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
  • Asia focused map inside light bulb

    Big pharma taps fast Asia innovation in search of next Keytruda

    BioWorld
    Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing